Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

DNA bases
• Source: Shutterstock

Verve Therapeutics is looking to submit its opt-in package to partner Eli Lilly after the announcement of positive data from the Phase Ib study of VERVE-102 in heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD), in the hopes of bringing the large pharma company on board with the in vivo gene editing program.

Key Takeaways
  • Verve announced positive results from the Phase Ib Heart-2 trial of VERVE-102, with competitive cholesterol lowering and clean safety for the gene-editing therapy.

The biotech announced 14 April initial data from 14 patients in the Phase Ib Heart-2 trial of VERVE-102, showing that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

More from Therapy Areas

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AbbVie’s big autoimmune CAR-T play; In Vivo CAR-T interest grows; China deal perspectives from BIO; global pharma interest in Korea undeterred; and a look at the biggest drug sales disappointments.